SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease

SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease

Artiva Biotherapeutics was featured in the San Diego Business Journal highlighting the Company’s strategic transition into autoimmune disease and the FDA Fast Track Designation for AlloNK® in rheumatoid arthritis. The story outlines how AlloNK is designed for outpatient use and underscores the significant unmet need in rheumatoid arthritis. It also includes perspectives from Artiva’s CEO Fred Aslan on making treatment more accessible in community settings and on the decision to focus first on rheumatoid arthritis, where many patients still lack effective options.

Read the full article here (subscription may be required).